Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Sopharma AD-Sofia's 3-Year RORE % for the quarter that ended in Mar. 2026 was 43.98%.
The industry rank for Sopharma AD-Sofia's 3-Year RORE % or its related term are showing as below:
WAR:SPH's 3-Year RORE % is ranked better than 83.64% of 110
companies
in the Medical Distribution industry
Industry Median: 14.155
vs WAR:SPH: 43.98
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Sopharma AD-Sofia 3-Year RORE % Related Terms
Sopharma AD-Sofia 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for Sopharma AD-Sofia's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WAR:SPH vs MCK, CAH, COR: 3-Year RORE % Comparison
For the Medical Distribution subindustry, Sopharma AD-Sofia's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sopharma AD-Sofia 3-Year RORE % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Sopharma AD-Sofia's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Sopharma AD-Sofia's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.
Sopharma AD-Sofia (WAR:SPH) has a 3-Year RORE % of 43.98 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Sopharma AD-Sofia and its competitors. According to the industry distribution chart, Sopharma AD-Sofia ranks #18 out of 110 companies in the Medical Distribution industry, placing it in the top 16.4%.
Is Sopharma AD-Sofia's 3-Year RORE % too high?
Sopharma AD-Sofia's current 3-Year RORE % is 43.98. The Medical Distribution industry median 3-Year RORE % is 14.16. Sopharma AD-Sofia's value of 43.98 is 210.7% above this industry median. Based on the distribution chart, Sopharma AD-Sofia ranks #18 out of 110 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Sopharma AD-Sofia has a GF Score™ of 70/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sopharma AD-Sofia's 3-Year RORE % compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Sopharma AD-Sofia ranks #18 out of 110 companies for 3-Year RORE %. This places Sopharma AD-Sofia in the top 16% of its industry — outperforming the majority of peers. The industry median 3-Year RORE % is 14.16. Sopharma AD-Sofia's value of 43.98 is 210.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Medical Distribution company?
The median 3-Year RORE % among Medical Distribution companies is 14.16, based on 110 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sopharma AD-Sofia's current 3-Year RORE % of 43.98 is 210.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Sopharma AD-Sofia and its competitors. For the Medical Distribution industry, the median 3-Year RORE % is 14.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sopharma AD-Sofia's current 3-Year RORE % is 43.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sopharma AD-Sofia stock overvalued right now?
Based on GuruFocus' analysis, Sopharma AD-Sofia (WAR:SPH) is currently considered Possible Value Trap. The stock's GF Value™ is zł13.43, compared to a current price of zł7.24 — trading 46.1% below its estimated fair value. The current 3-Year RORE % is 43.98 and 210.7% above the Medical Distribution industry median of 14.16. Sopharma AD-Sofia's overall GF Score™ is 70/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Sopharma AD-Sofia (WAR:SPH), the current 3-Year RORE % is 43.98 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sopharma AD-Sofia (WAR:SPH) Overvalued in 2026?
Based on GuruFocus' analysis, Sopharma AD-Sofia stock appears to be undervalued.
The current stock price of zł7.24 is trading 46.1% below its estimated GF Value™ of zł13.43.
GuruFocus considers Sopharma AD-Sofia to be Possible Value Trap.
Key valuation signals for WAR:SPH:
3-Year RORE %: 43.98
GF Value™: zł13.43 vs. price of zł7.24 (46.1% below fair value)
Industry Position: 210.7% above the Medical Distribution median (#18 of 110)
No single metric tells the full story. See the WAR:SPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sopharma AD-Sofia is a company engaged in the production of pharmaceutical products. Its principal activities include the production and trade of medicinal substances and finished drug forms; and research and development as well as engineering and implementation activities in the field of medicinal products. It is also focused on the distribution of pharmaceuticals like medical supplies, sanitary materials, vitamins, food supplements, and cosmetics. The company's segments are the Production of pharmaceutical products; Distribution of pharmaceutical products. It generates the majority of its revenue from the Distribution of pharmaceutical products.
70GF Score
Get the complete analysis for WAR:SPH
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:SPH has been successfully added to your 
